Clinical Trials Browser

Interventional × Vemurafenib × Endocrine × Clear all

NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Phase 2 Recruiting

21 enrolled

EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT03181100 2026-01-09

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Phase 2 Active not recruiting

50 enrolled

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT05768178 2025-11-24

DETERMINE

Phase 2/3 Recruiting

30 enrolled

CNSDermatologicEndocrineGastrointestinalGynecologicHead & NeckMyeloidOther hematologic neoplasmPlasma cellThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Glioma, Laryngeal Neoplasms, Melanoma, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Ovarian Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms, Erdheim-Chester Disease, Thyroid Carcinoma, Anaplastic

NCT01709292 2025-10-27

Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

Phase 2 Active not recruiting

24 enrolled

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms

NCT04462471 2025-09-08

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Phase 1 Completed

8 enrolled 8 charts

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms